XERIS Pharmaceuticals Inc (XERS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:XERIS Pharmaceuticals Inc (XERS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8069
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of ultra concentrated formulations of proteins, peptides, antibodies and small molecules using syringes, multi-dose pens, auto-injectors and pumps. Its products are used for various therapeutic areas, including severe hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, acute repetitive seizures and type 1/type 2 blood sugar control. The company caters caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.

XERIS Pharmaceuticals Inc (XERS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
XERIS Pharma Raises USD10 Million in Series C Equity Financing 12
Xeris Pharma Raises Additional USD30 Million in Series C Financing 13
Xeris Pharma Raises Additional USD4 Million in Venture Financing 15
Xeris Pharmaceuticals Raises USD41 Million in Series C Financing Round 16
Xeris Pharma Raises USD7.3 Million in Series B Financing 17
XERIS Pharma Raises USD0.2 Million in Venture Financing 18
Partnerships 19
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 19
Juvenile Diabetes Research Partners with Xeris Pharma and LATITUDE Pharma 20
Equity Offering 21
Xeris Pharma Raises USD98.3 Million in IPO of Shares 21
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 22
XERIS Pharmaceuticals Inc – Key Competitors 23
XERIS Pharmaceuticals Inc – Key Employees 24
XERIS Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Aug 13, 2018: Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights 26
Corporate Communications 27
Sep 07, 2017: Xeris Pharmaceuticals Appoints John P. Schmid to Board of Directors 27
Jan 09, 2017: Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO 28
Product News 29
06/16/2017: Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program 29
02/15/2018: Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia 31
Clinical Trials 32
Aug 17, 2018: Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon 32
Jul 18, 2018: Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus 33
Jun 25, 2018: Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen 34
Feb 08, 2018: FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH) 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XERIS Pharma Raises USD10 Million in Series C Equity Financing 12
Xeris Pharma Raises Additional USD30 Million in Series C Financing 13
Xeris Pharma Raises Additional USD4 Million in Venture Financing 15
Xeris Pharmaceuticals Raises USD41 Million in Series C Financing Round 16
Xeris Pharma Raises USD7.3 Million in Series B Financing 17
XERIS Pharma Raises USD0.2 Million in Venture Financing 18
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 19
Juvenile Diabetes Research Partners with Xeris Pharma and LATITUDE Pharma 20
Xeris Pharma Raises USD98.3 Million in IPO of Shares 21
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 22
XERIS Pharmaceuticals Inc, Key Competitors 23
XERIS Pharmaceuticals Inc, Key Employees 24

List of Figures
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[XERIS Pharmaceuticals Inc (XERS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Exalenz Bioscience Ltd (EXEN):医療機器:M&Aディール及び事業提携情報
    Summary Exalenz Bioscience Ltd (Exalenz) carries out the development and commercialization of advanced medical systems for a range of gastrointestinal (GI) tract and liver disorders. The company harnesses its BreathID technology platform for assessment and monitoring of functional diseases. Its flag …
  • Meridian Energy Limited:企業の戦略・SWOT・財務情報
    Meridian Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Meridian Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BioMotiv LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary BioMotiv LLC (BioMotiv) is a therapeutics licensing and development service provider. The company offers therapeutics across wide disease areas including proteins, small molecules, antibodies, and nucleotides. It portfolio includes psoriasis, inflammatory bowel diseases, cancer, retinitis pi …
  • Spark Therapeutics Inc (ONCE):企業の財務・戦略的SWOT分析
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • Accugenomics Inc-医療機器分野:企業M&A・提携分析
    Summary Accugenomics Inc (Accugenomics) is a provider of molecular diagnostics for cancer. The company develops and markets gene expression tests to diagnose and monitor cancer treatment. It offers gene expression tests including lung cancer risk test, standardized BCR-ABL molecular diagnostics test …
  • Sao Martinho SA (SMTO3):企業の財務・戦略的SWOT分析
    Sao Martinho SA (SMTO3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • IHI Corp (7013):電力:M&Aディール及び事業提携情報
    Summary IHI Corp (IHI) is a heavy machinery manufacturer. It provides technology oriented products and services to customers in the public, private and industrial sectors across the world. The group designs and manufactures a diverse range of products that includes ships and offshore facilities, str …
  • Argent Trading Llc:企業の戦略・SWOT・財務分析
    Argent Trading Llc - Strategy, SWOT and Corporate Finance Report Summary Argent Trading Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Rakuten, Inc. (4755):企業の財務・戦略的SWOT分析
    Rakuten, Inc. (4755) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • KPJ Healthcare Berhad (KPJ):企業の財務・戦略的SWOT分析
    Summary KPJ Healthcare Berhad (KPJ) is a healthcare service provider that offers medical services. The center offers services in the areas of anaesthesiology, cardiology and cardiothoracic surgery, child psychiatry, clinic pathology, occupational health services, orthopaedic and trauma surgery, diet …
  • Japan Airport Terminal Co Ltd:企業の戦略・SWOT・財務分析
    Japan Airport Terminal Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Airport Terminal Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Arab International Bank:企業の戦略・SWOT・財務情報
    Arab International Bank - Strategy, SWOT and Corporate Finance Report Summary Arab International Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Asklepios BioPharmaceutical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Asklepios Biopharmaceutical Inc (Asklepios Biopharmaceutical) is a drug development company that develops and markets novel protein and cellular based therapies. The company’s products include BNP-CHF, biostrophin, AskBio009, BNP-FVIII, BNP-RP, BNP-TLE, and BNP-OA. It also provides products …
  • PLC SPA (IIN):電力:M&Aディール及び事業提携情報
    Summary PLC SPA (PLC Group) formerly Industria e Innovazione S.p.A, is a provider of design, installation, and maintenance services for electrical infrastructures and renewable energy plants. The company’s service offerings include engineering, procurement, and construction (EPC); manufacturing and …
  • Varian Medical Systems Inc (VAR):企業の財務・戦略的SWOT分析
    Varian Medical Systems Inc (VAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • British American Tobacco Plc (BATS):企業の財務・戦略的SWOT分析
    British American Tobacco Plc (BATS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Clark Public Utilities:企業の戦略的SWOT分析
    Clark Public Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • NicozDiamond Insurance Limited:企業の戦略・SWOT・財務分析
    NicozDiamond Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary NicozDiamond Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Amneal Pharmaceuticals Inc (AMRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Amneal Pharmaceuticals Inc (Amneal) formerly Amneal Pharmaceuticals LLC, is an integrated specialty pharmaceutical company that produces generic, specialty and biosimilar medicines. Its product portfolio includes generic and specialty drugs in the therapeutic areas of analgesic, antibiotic, …
  • AIT Austrian Institute of Technology GmbH-医療機器分野:企業M&A・提携分析
    Summary AIT Austrian Institute of Technology GmbH (AIT) is a research and technology institute that provides research development services in various fields. The institute offers research on health and environment, energy, mobility, digital safety and security, and innovation systems. Its health and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆